Somatostatin Analogs for Pancreatic Neuroendocrine Tumors When KI-67 Is ≥10%
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 Is ≥10%?
Oncologist 2020 Dec 10;[EPub Ahead of Print], E Merola, T Alonso Gordoa, P Zhang, T Al-Toubah, E Pelle, A Kolasińska-Ćwikła, WT Zandee, FM Laskaratos, L de Mestier, A Lamarca, J Hernando, JB Cwikla, J Strosberg, WW de Herder, M Caplin, M Cives, RS van LeeuwaardeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.